Company: XOMAP
Filing Date: 2025-09-03
Form Type: SC TO-T/A
Source: 0001193125-25-195061
Chunk: 2

Company: XOMA Royalty Corp
Filing Date: 2025-09-03
Form: SC TO-T/A
Chunk 2
---
 to them in the Schedule TO. The Schedule TO is hereby amended and supplemented as follows: ITEMS 1 THROUGH 9 AND 11 Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

| I. | The first bullet point beginning on Page 3 (and continuing onto Page 4) of the Offer to Purchase in the                                                          
 question “What is the CVR and how does it work?” of the Section entitled “Summary Term Sheet” is hereby amended and restated in its entirety to read as follows: |

At or prior to the Acceptance Time, Purchaser, the rights agent (the “ Rights Agent”) and the representative of the holders of the CVRs (the “ Representative”) will enter into the CVR Agreement, governing the terms of the CVRs. Each CVR will represent a contractual right to receive contingent cash payments equal to a pro rata share of: (i) 100% of the amount by which the Closing Net Cash, as adjusted for any permitted deductions under CVR Agreement made within ninety (90) days following the Closing Date, in excess of the Closing Net Cash as finally determined in accordance with the Purchase Agreement (such proceeds, “ Additional Net Cash Proceeds”), (ii) (A) 100% of the net proceeds, calculated in accordance with the CVR Agreement, if any, from any sale, transfer, license or other disposition (a “ Disposition”) of CVR Products prior to the Closing and (B) 75% of the net proceeds, calculated in accordance with the CVR Agreement, if any, from any Disposition of CVR Products occurring following the Closing, in each case for the period beginning at the Closing Date and ending on the 10th anniversary of the Closing Date (such proceeds, “ Disposition Proceeds”), and (iii) 75% of the net proceeds, calculated in accordance with the CVR Agreement, if any, from LAVA’s collaborations (A) with Pfizer Inc. (formerly Seagen Inc.) to develop, manufacture and commercialize EGFRd2 (PF-8046052)and (B) with Johnson & Johnson (formerly Janssen) for the discovery and development of novel bispecific antibody-based T cell engagers for the treatment of cancer, including JNJ-89853413((A) and (B) together, the “ Existing Partnership Agreements”), in each